Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls

Executive Summary

FDA's decision to create a class Risk Evaluation and Mitigation Strategy for all transmucosal fentanyl products indicates that the agency could take a similar strategy with the extended-release opioids.

You may also be interested in...

FDA Standardizing REMS Re-Enrollment Procedures

Common registration site for participants in REMS was endorsed by several panel members during a joint meeting of the Drug Safety and Risk Management and Dermatologic and Ophthalmic Drugs Advisory Committees.

iPLEDGE Again On FDA Advisory Agenda, This Time As An Example

"REMS-related topics" is the theme of a joint FDA advisory committee meeting Dec. 1 focused on the landmark iPLEDGE program as an example of the effect such programs have on the health care system.

Drug Patch Manufacturers Can Skip Quality By Design Approach, FDA Says

Final guidance softens a recommendation that manufacturers of transdermal and transmucosal drug delivery systems and topical patches use a Quality by Design approach.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts